Literature DB >> 33221802

A Kidney Transplant Recipient with Recurrent Henoch-Schönlein Purpura Nephritis Successfully Treated with Steroid Pulse Therapy and Epipharyngeal Abrasive Therapy.

Mika Fujimoto1, Kan Katayama2, Kouhei Nishikawa3, Shoko Mizoguchi1, Keiko Oda1, Yosuke Hirabayashi1, Yasuo Suzuki1, Ayumi Haruki1, Takayasu Ito1, Tomohiro Murata1, Eiji Ishikawa1, Yoshiki Sugimura3, Masaaki Ito1.   

Abstract

There is no specific treatment for recurrent Henoch-Schönlein purpura nephritis (HSPN) in a transplanted kidney. We herein report a case of a kidney transplant recipient with recurrent HSPN that was successfully treated with steroid pulse therapy and epipharyngeal abrasive therapy (EAT). A 39-year-old Japanese man developed HSPN 4 years ago and had to start hemodialysis after 2 months despite receiving steroid pulse therapy followed by oral prednisolone, plasma exchange therapy, and cyclophosphamide pulse therapy. He had undergone tonsillectomy 3 years earlier in the hopes of achieving a better outcome of a planned kidney transplantation and received a living-donor kidney transplantation from his mother 1 year earlier. Although there were no abnormalities in the renal function or urinalysis 2 months after transplantation, a routine kidney allograft biopsy revealed evidence of mesangial proliferation and cellular crescent formation. Mesangial deposition for IgA and C3 was noted, and he was diagnosed with recurrent HSPN histologically. Since the renal function and urinalysis findings deteriorated 5 months after transplantation, 2 courses of steroid pulse therapy were performed but were ineffective. EAT using 0.5% zinc chloride solution once per day was combined with the third course of steroid pulse therapy, as there were signs of chronic epipharyngitis. His renal function recovered 3 months after daily EAT and has been stable for 1.5 years since transplantation. Daily EAT continued for >3 months might be a suitable strategy for treating recurrent HSPN in cases of kidney transplantation.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  Epipharyngeal abrasive therapy; Henoch-Schönlein purpura nephritis; Kidney transplantation; Recurrent glomerulonephritis; Steroid pulse therapy

Year:  2020        PMID: 33221802     DOI: 10.1159/000511166

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  3 in total

1.  Epipharyngeal Abrasive Therapy Down-regulates the Expression of SARS-CoV-2 Entry Factors ACE2 and TMPRSS2.

Authors:  Kensuke Nishi; Shohei Yoshimoto; Soichiro Nishi; Toshiyuki Tsunoda; Jun Ohno; Michinobu Yoshimura; Kenji Hiromatsu; Takafumi Yamano
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

2.  Development and validation of a nomogram to predict recurrence in children with Henoch-Schönlein purpura.

Authors:  Danyang Song; Yajing Jiang; Qiuju Zhao; Jinling Li
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

3.  Epipharyngeal Abrasive Therapy (EAT) Reduces the mRNA Expression of Major Proinflammatory Cytokine IL-6 in Chronic Epipharyngitis.

Authors:  Kensuke Nishi; Shohei Yoshimoto; Soichiro Nishi; Tatsuro Nishi; Ryushiro Nishi; Takayuki Tanaka; Toshiyuki Tsunoda; Kazuaki Imai; Hiroaki Tanaka; Osamu Hotta; Ayaki Tanaka; Kenji Hiromatsu; Senji Shirasawa; Takashi Nakagawa; Takafumi Yamano
Journal:  Int J Mol Sci       Date:  2022-08-16       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.